mirati.comMirati Therapeutics, Inc. | Relentless Focus on Innovation | Targeted Oncology

Mirati Therapeutics Investors & Media Overview Resources Information Request Form Email Alerts Investor Contacts Careers Contact Us Home Science Pipeline Programs KRAS Inhibitors KRAS G12C Inhibitor KRAS G12D Inhibitor PRMT5 Inhibitor Clinical Trials Presentations & Publications Patients & Caregivers Patient Stories Lung Cancer Resources Medicines Authorized Distributors Responsibility Mirati Gives Transparency Diversity, Equity and Inclusion Sponsorships & Grants Declaration of Compliance Stories About Mission & Vision Business Development Home Science Back Overview Pipeline Programs Back Overview KRAS Inhibitors Back Overview KRAS G12C Inhibitor KRAS G12D Inhibitor PRMT5 Inhibitor Clinical Trials Presentations and Publications Patients & Caregivers Back Overview Patient Stories Lung Cancer Resources Medicines Back Overview Authorized Distributors Responsibility Back Overview Mirati Gives Transparency Diversity, Equity and Inclusion Sponsorships & Grants Mirati Declaration of Compliance Stories About Back Mission & Vision Business Development Investors & Media Back Overview Resources Back Information Request Form Email Alerts Investor Contacts Careers Contact Us Sorry, your browser doesn’t support embedded videos. The FDA has approved KRAZATI Sorry, your browser doesn’t support embedded videos. We’re tackling cancer head-on At Mirati, we convert possibility into reality by developing best-in-class targeted therapies to improve the lives of patients. Sorry, your browser doesn’t support embedded videos. Video: Learn more about our mission and commitment to patients Watch more At Mirati, we convert possibility into reality by developing best-in-class targeted therapies to improve the lives of patients. Our Programs KRAS Our scientists are rigorously advancing research and development programs targeting the KRAS G12C and KRAS G12D mutations. Explore our KRAS programs MRTX1719 MRTX1719 is an investigational, internally discovered synthetic lethal PRMT5 inhibitor for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers. Explore our MRTX1719 program Mirati is developing a pipeline of novel therapeutics. Explore the Pipeline Become part of something bigger . Explore Careers at Mirati 01/10/2024 European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation 11/10/2023 Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure 11/06/2023 Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates 11/03/2023 Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Mirati Therapeutics © Copyright 2024 - Mirati Therapeutics, Inc. 1-844-MIRATI-1 (1-844-647-2841) info@mirati.com Terms of Use Privacy Cookies Purchase Order Terms Expanded Access Community Guidelines References Ledford, Heidi. Cancer: The Ras renaissance.” Nature 520.7547 (2015): 278-280. Matikas, Alexios et al. Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.” Crit Rev Oncol Hematol 110 (2017): 1-12. Ostrem, Jonathan M., Shokat, Kevan M. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.” Nat Rev Drug Discov 15.11 (2016): 771-785. Bos, Johannes L. ras oncogenes in human cancer: a review.” Cancer Res 49.17 (1989): 4682-4689 Simanshu, Dhirendra K. et al. RAS proteins and their regulators in human disease.” Cell 170.1 (2017): 17-33. Beganoyic S. CLINICAL SIGNIFICANCE OF THE KRAS MUTATION. Bosn J Basic Med Sci. 2009;9(Suppl 1):S17-S20. Mirati estimates based on epidemiology data reported in Globocan 2022 (accessed 2019) and frequencies by mutation; Europe includes EU, Russia and 10 additional European countries; RET estimate does not include thyroid cancer. Rounded to the nearest 1,000. Zehir A et al, Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703-713” Campbell et al, Nature Genetics 2016 Distinct patterns of somatic genome alterations in lung adenocarcinomas” Bailey P et al, Nature 2016 Genomic analyses identify molecular subtypes of pancreatic cancer” Hallin J. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discovery, 2019. Mirati Therapeutics. Data on File. Percent et al. Phase III trial of sitravatinib plus nivolumab vs. docetaxel for treatment of NSCLC after platinum-based chemotherapy and immunotherapy (SAPPHIRE). Journal of Clinical Oncology 2020 38:15_suppl, TPS9635-TPS9635. Pircher et al., Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints. Int J Mol Sci, 2017. 18(11). Akalu, Y.T., C.V. Rothlin, and S. Ghosh, TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol Rev, 2017. 276(1): p. 165-177. Kwilas, A.R., R.N. Donahue, K.Y. Tsang, and J.W. Hodge, Immune consequences of tyrosinekinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenviron, 2015. Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-1218. doi:10.1126/science.aad5214 Marjon K, Cameron MJ, Quang P, et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis. Cell Rep. 2016;15(3):574-587. doi:10.1016/j.celrep.2016.03.043 Mavrakis KJ, McDonald ER 3rd, Schlabach MR, et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science. 2016;351(6278):1208-1213. doi:10.1126/science.aad5944 Han G, Yang G, Hao D, et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 Sep 23;12(1):5606. doi: 10.1038/s41467-021-25894-9. Smith C.R., Aranda R, Bobinski T.P., Briere D.M., Burns A.C., et al. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers. J Med Chem. 2022 Jan 18. doi: 10.1021/acs.jmedchem.1c01900. Online ahead of print. Close this module Mirati is now a Bristol Myers Squibb company Select Accept for Information about Mirati. To learn more about Bristol Myers Squibb Click Here...